HBV Disease Progression
Low Vitamin D Linked to Greater Hepatitis B Virus Replication
- Details
- Category: HBV Disease Progression
- Published on Thursday, 13 June 2013 00:00
- Written by Liz Highleyman
Low blood levels of 25-hydroxyvitamin D were strongly associated with higher hepatitis B virus (HBV) viral load in a study of more than 200 untreated patients described in the May 22, 2013 advance online edition of Hepatology.
Everolimus (Zortress) Approved to Prevent Liver Transplant Rejection
- Details
- Category: Liver Transplant - HBV
- Published on Wednesday, 20 February 2013 00:00
- Written by Novartis
The U.S. Food and Drug Administration (FDA) this month approved the immunosuppressant drug everolimus (brand name Zortress) for preventing organ rejection in people who undergo liver transplantation. A recent large study found that everolimus was easier on the kidneys when used in combination with low-dose tacrolimus (Prograf).
Liver Disease Is Leading Cause of Death for People with Chronic Hepatitis B
- Details
- Category: HBV Disease Progression
- Published on Tuesday, 15 January 2013 00:00
- Written by Liz Highleyman
Advanced liver disease caused by hepatitis B virus (HBV) -- including hepatocellular carcinoma (HCC) and decompensated cirrhosis -- accounted for more than 40% of deaths of people with chronic hepatitis B in a large health maintenance organization, researchers reported in the December 12, 2012, advance online edition of Hepatology.
Heavy Alcohol Use Increases Liver Cancer Risk for People with Hepatitis B
- Details
- Category: HBV Disease Progression
- Published on Thursday, 24 January 2013 00:00
- Written by Liz Highleyman
Hepatitis B patients with liver cirrhosis who consumed large amounts of alcohol were more likely to develop hepatocellular carcinoma (HCC) than people who drank less, according to a report in the December 6, 2012, online edition of the Journal of Hepatology. However, antiviral treatment can help prevent liver cancer.
AASLD 2012: Patients with Cirrhosis Can Respond Well to Boceprevir or Telaprevir with Careful Monitoring
- Details
- Category: Liver Cancer/HCC
- Published on Tuesday, 04 December 2012 00:00
- Written by Liz Highleyman
Real-world experience in the French early-access CUPIC study shows that hepatitis C patients with advanced liver damage can achieve good response to interferon-based triple-therapy including boceprevir (Victrelis) or telaprevir (Incivek), although adverse events are common, according to a presentation at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) last month in Boston.
More Articles...
- AASLD 2012: Brivanib Fails to Match Sorafenib for Liver Cancer, but Tivatinib Looks Promising
- AASLD 2012: When Are HCV Direct-Acting Antivirals Needed, Who Should Be Prioritized?
- Researchers Grow Liver Tissue from Pluripotent Stem Cells
- HBV Genotype Affects Hepatitis B Disease Progression and Outcomes
Web Design and Development by